Preoperative short‐course radiotherapy followed by chemotherapy and PD‐1 inhibitor administration for locally advanced rectal cancer: A study protocol of a randomized phase II/III trial (STELLAR II study)
Colorectal Disease · 2024
DOI: 10.1111/codi.17090 ↗At a glance
Studienprotokoll in Colorectal Disease, 2024. Written by Wenjue Zhang and 19 co-authors. Institution: Department of Radiation Oncology, National Cancer Center/National Clinical Research Centre for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Ac…. Major MEDLINE topics: Clinical Trials, Phase II as Topic, Immune Checkpoint Inhibitors, Neoadjuvant Therapy, Rectal Neoplasms. Cited 13 times so far (Crossref); 32 references. Funded by: National Natural Science Foundation of China.
Topics: Onkologische Pflege
Abstract (original language)
Aim
For patients with locally advanced rectal cancer, previous STELLAR studies have shown that a new adjuvant treatment paradigm of short‐course radiotherapy followed by neoadjuvant chemotherapy can achieve pathological complete response rates superior to those of standard care; however, the 3‐year DFS is inferior to neoadjuvant concurrent radiotherapy. Recent studies have shown that immune checkpoint inhibitors may improve the prognosis of rectal cancer and have good synergy with radiotherapy. Therefore, neoadjuvant chemotherapy combined with immune checkpoint inhibitors after a short course of radiotherapy has the potential to further improve complete response rates and prognosis.
Method
The STELLAR II study is a multicentre, open label, two‐arm randomized, phase II/III trial of short‐course radiotherapy followed by neoadjuvant chemotherapy concurrent with immunotherapy for locally advanced rectal cancer. A total of 588 patients with locally advanced rectal cancer (LARC) will be randomly assigned to the experimental and control groups. The experimental group will receive short‐course radiotherapy and neoadjuvant chemotherapy in combination with sindilizumab, while the control group will receive short‐course radiotherapy and neoadjuvant chemotherapy. Both groups will subsequently receive either total rectal mesenteric resection or a watch & wait (W&W) strategy. The phase II primary endpoint is the complete remission rate, and the secondary endpoints include grade 3–4 adverse events, perioperative complications, R0 resection rate, overall survival, local recurrence rate, distant metastasis rate and quality of life score. A seamless phase II/III randomized controlled design will be used to investigate the effectiveness and safety of the TNT strategy with the addition of immunotherapy. The trial opened, and the first patient was recruited on 31 August 2022. Trial registration number and date of registration: ClinicalTrials.gov NCT05484024 , 29 July 2022.
Discussion
The STELLAR II trial will prospectively evaluate the efficacy of TNT treatment strategies that incorporate immune checkpoint inhibitors. The trial will yield important information to guide routine management of patients with local advanced rectal cancer.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Radiation Oncology, National Cancer Center/National Clinical Research Centre for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen,…
- State Key Laboratory of Molecular Oncology, Department of Radiation Oncology, National Cancer Center/National Clinical Research Centre for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Med…
- Department of Radiation Oncology, Xijing Hospital, Air Force Medical University, Xi'an, China.
- Department of Radiation Oncology, Jilin Provincial Cancer Hospital, Changchun, China.
- Department of Oncology, Affiliated Hospital of Guizhou Medical University, Guiyang, China.
- State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Centre/National Clinical Research Centre for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medic…
ORCID profiles: Wenjue Zhang, Huiying Ma
Funding
- National Natural Science Foundation of China
Cite
APA
Zhang, W., Tang, Y., Wei, L., Liu, S., Wang, W., Chi, Y., Wang, Y., Kang, W., Huang, W., Deng, F., Li, H., Ma, H., Jiang, L., Ding, Z., Feng, L., Li, Y., Chen, Y., Zhou, H., Hu, C., & Jin, J. (2024). Preoperative short‐course radiotherapy followed by chemotherapy and PD‐1 inhibitor administration for locally advanced rectal cancer: A study protocol of a randomized phase II/III trial (STELLAR II study). Colorectal Disease. https://doi.org/10.1111/codi.17090
Vancouver
Zhang W, Tang Y, Wei L, Liu S, Wang W, Chi Y, et al. Preoperative short‐course radiotherapy followed by chemotherapy and PD‐1 inhibitor administration for locally advanced rectal cancer: A study protocol of a randomized phase II/III trial (STELLAR II study). Colorectal Disease. 2024. doi:10.1111/codi.17090
BibTeX
@article{Zhang2024,
author = {Zhang, Wenjue and Tang, Yuan and Wei, Lichun and Liu, Shixin and Wang, Wenling and Chi, Yihebali and Wang, Ying and Kang, Wenyan and Huang, Wenting and Deng, Feiyan and Li, Haoyue and Ma, Huiying and Jiang, LiMing and Ding, Zhen and Feng, Lingling and Li, Yexiong and Chen, Yinggang and Zhou, Haitao and Hu, Chen and Jin, Jing},
title = {Preoperative short‐course radiotherapy followed by chemotherapy and PD‐1 inhibitor administration for locally advanced rectal cancer: A study protocol of a randomized phase II/III trial (STELLAR II study)},
journal = {Colorectal Disease},
year = {2024},
doi = {10.1111/codi.17090}
}
EUVIMED